| Literature DB >> 26850322 |
Anna S Świerzko1, Agnieszka Szala-Poździej1, David C Kilpatrick2, Michał Sobociński3, Karolina Chojnacka4, Anna Sokołowska1, Mateusz Michalski5, Karolina Mazerant1, Jens C Jensenius6, Misao Matsushita7, Wojciech R Krajewski3, Jerzy Szczapa4, Leokadia Bąk-Romaniszyn8, Krzysztof Zeman9, Maciej Cedzyński10.
Abstract
Infections are a major cause of childhood mortality. We investigated components of the lectin pathway of complement activation in the context of sepsis at both genetic and protein levels in neonates, infants and older children. Major components of the lectin pathway and two genes for Toll-like receptors were studied in 87 neonates with confirmed sepsis and compared with 40 babies with infections who did not develop sepsis (disease controls) and 273 infection-free neonatal controls. A second cohort comprised 47 older children with sepsis and 87 controls. Low MBL-conferring genotypes (LXA/O+O/O) were more frequent in sepsis patients than in healthy controls but no significant differences in the frequency of SNPs of other lectin pathway genes (FCN1, FCN2, FCN3, MASP1/3, MASP2) or TLR receptor genes (TLR2, TLR4) were found. One case of primary MASP-2 deficiency was found among healthy pre-terms and one neonate suffering from SIRS was heterozygous for the rare FCN1 gene mutation, +6658 G>A. Generally, sepsis was associated with low serum MBL and low ficolin-2 concentrations on admission. Among neonates, ficolin-1 and MASP-2 levels were elevated in sepsis relative to healthy, but not disease, controls. Unlike neonates, ficolin-3 and MASP-2 levels were lower in older patients than in healthy controls while no difference was found for ficolin-1. With the possible exception of MBL, inherited lectin pathway insufficiencies do not seem to predispose to sepsis, rather changes in protein concentrations reflect alterations in disease course.Entities:
Keywords: ); Complement; Ficolin; Innate immunity; MASP; Mannose-binding lectin (mannan-binding lectin, MBL; Sepsis
Mesh:
Substances:
Year: 2016 PMID: 26850322 DOI: 10.1016/j.imbio.2016.01.003
Source DB: PubMed Journal: Immunobiology ISSN: 0171-2985 Impact factor: 3.144